Clinical trials: PME
Progressive Myoclonus Epilepsy Type 1, EPM1
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)
The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all…
- Conditions
- Progressive Myoclonus Epilepsy Type 1, EPM1, CSTB-related Disease, Myoclonus Epilepsies, Progressive
- Trial name
- EPM1 (NCT06593951)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston Children's Hospital
ICD Indication
Linox Smart S DX PME/Master Study
The objective of this study is to prove the safety and efficacy of the Linox smart S DX ICD lead.
- Trial name
- NCT01090401
- Testing
- Linox smart S DX
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Biotronik SE & Co. KG
Familial Dementia With Neuroserpin Inclusion Bodies, Nervous System Heredodegenerative Disorder
Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies
The purpose of this study is to learn more about the medical problems and the genetic factors involved in a recently defined form of inherited dementia called "familial dementia with neuroserpin inclusion bodies (FDNIB)."…
- Trial name
- NCT00006176
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cystoid Macular Edema
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.
- Trial name
- NCT00406172
- Testing
- Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Alcohol, Message Perception
Alcohol and Cancer Message Testing Experiment
Alcohol increases the risk for at least seven cancers, yet recent estimates suggest only between one-third and one-half of US adults are aware of this risk.
- Conditions
- Alcohol, Message Perception, PME
- Trial name
- NCT07848906
- Testing
- Alcohol health harm message exposure
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.
- Trial name
- NCT00357669
- Testing
- Brivaracetam 25 mg, Brivaracetam 50 mg
- Where
- 13 sites in Finland, France and 5 more
- Volunteers
- 50 people
- Sponsor
- UCB Pharma SA
Healthy People
Pain Modulation Effectiveness (PME)
Conditioned pain modulation (CPM) is the behavioral measure of diffuse noxious inhibitory control (DNIC), an endogenous pain inhibitory pathway in which pain inhibits pain.
- Trial name
- PME (NCT05783362)
- Testing
- Conditioned Pain Modulation (CPM)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Florida
Unverricht-Lundborg Disease
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.
- Trial name
- NCT03351569
- Testing
- Intravenous immunoglobulin
- Volunteers
- 1 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Mantova
Cardiac Disease
Comparitive Effectiveness of PME Versus Transthoracic Echocardiogram (TTE)
A new hand held pocket echo device (GE Vscan) has now become available to clinicians, with limited data available comparing the effectiveness of this device as a screening tool when compared to traditional transthoracic…
- Trial name
- NCT02141269
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Scripps Translational Science Institute
Unverricht-Lundborg Syndrome
Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
The progressive myoclonus epilepsy of the Unverricht-Lundborg disease (ULD) type is an autosomal recessive disease characterized by progressive stimulus-sensitive and action-related myoclonic jerks.
- Trial name
- NCT00639119
- Testing
- Ropinirole
- Where
- Finland
- Volunteers
- 16 people
- Sponsor
- University of Turku
Safety and Efficacy of the Lumax 740 ICD Family
Lumax 740 Master Study
The objective of this study is to prove the safety and efficacy of the Lumax 740 ICD family. Primarily, the newly implemented RV/LV Capture Control algorithm is evaluated, which automatically measures the RV/LV threshold and…
- Trial name
- Lumax 740 (NCT01454050)
- Where
- Germany
- Volunteers
- 189 people
- Sponsor
- Biotronik SE & Co. KG
PME, Food Choice
Nutri-score Labelling in a UK Restaurant Setting: a Randomised Control Trial
An experiment exploring the perceived effectiveness of Nutri-score food labels with calorie labelling compared to calorie labelling only on food choice and consumption in a real-world setting
- Conditions
- PME, Food Choice, Food Labelling
- Trial name
- NCT06923241
- Testing
- menu labelling type
- Where
- United Kingdom
- Volunteers
- 672 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
- Trial name
- NCT00368251
- Testing
- BRV 2.5 mg, BRV 25 mg, BRV 50 mg
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
Neuronal Ceroid Lipofuscinosis, Batten Disease
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
This is an observational study that aims at assessing the natural history of NCL diseases as part of the international DEM-CHILD Database. 1.
- Conditions
- Neuronal Ceroid Lipofuscinosis, Batten Disease, CLN1 Disease, CLN2 Disease
- Trial name
- NCT04613089
- Testing
- Natural History
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer
CAIman 5 Articulating Maryland in coloRECTAL Cancer Surgery
This voluntary study is part of a Post-Market-Surveillance plan to proactively collect clinical data for the use of Caiman 5 articulating Maryland in colorectal surgery under daily clinical routine.
- Trial name
- CAIRECTAL (NCT04175756)
- Testing
- Caiman 5 articulating Maryland
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Aesculap AG
Lafora Disease
Intravenous VAL-1221 Lafora Expanded Access Protocol
Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP).
- Trial name
- LEAP (NCT05930223)
- Testing
- VAL-1221
- Sponsor
- Parasail, LLC